ClinicalTrials.gg
Sign In

BiologicalDrug

Allogeneic Anti-CD19 T-cells ThisCART19A clinical trials

studies test it
10
open now
5
in phase 3
0
first study started
2022

Keep track of what changes. Save the Allogeneic Anti-CD19 T-cells ThisCART19A studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Name

ThisCART19A
10

Studies by the year they started

10 studies that test it; most in 2022 (7)

Studies that test Allogeneic Anti-CD19 T-cells ThisCART19A, by start year
YearStudies
20227
20231
20242

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
9
Phase 2
1

What it is tested for

Each study’s main condition, where its own words name it.

Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Anemia, Hemolytic, Autoimmune
1
Lymphoma, B-Cell
1
Lymphoma, Non-Hodgkin
1
Lymphoma, AIDS-Related
1

Who runs them

Industry 1 · Other 9

Zhejiang University (3) · Henan Cancer Hospital (1) · Fundamenta Therapeutics, Ltd. (1) · Zhengzhou University (1) · The First Affiliated Hospital of Soochow University (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Chongqing University Cancer Hospital (1) · He Huang (1)

Often tested with

Tested in the same studies.

Olverembatinib (1)

Studies

Open first, then newest update. How each study uses Allogeneic Anti-CD19 T-cells ThisCART19A is read from its arms, and is right about nine times in ten.

Testing it · 10